STARD7

Across TCGA pan-cancer cohorts, STARD7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STARD7 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher STARD7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STARD7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, GBM, and OV are the cancer types where STARD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.906	0.562	.004	27	view →
GBM	DFS	Median	All	0.222	0.511	.001	16	view →
OV	DFS	Tertile	All	0.751	1.000	.035	4	view →
PDAC	OS	Quartile	II,III,IV	0.350	0.698	.012	4	view →
LUAD	DFS	Tertile	All	0.973	0.894	.016	2	view →
LSCC	DFS	Quartile	All	0.945	0.707	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STARD7–HNSC (DFS)

Open the HNSC breakdown →